The relationship between tissue inhibitor of metalloproteinases-1 and KCNJ5 mutation in aldosterone-producing adenoma patients
- PMID: 39690251
- DOI: 10.1038/s41440-024-02030-w
The relationship between tissue inhibitor of metalloproteinases-1 and KCNJ5 mutation in aldosterone-producing adenoma patients
Abstract
KCNJ5 somatic mutations in aldosterone-producing adenoma (APA) are linked to higher left ventricular mass index (LVMI) and worse diastolic function. We previously identified an association between plasma tissue inhibitor of metalloproteinases-1 (TIMP-1) and an aldosterone-induced increase in LVMI and diastolic dysfunction. This study aimed to investigate the association between the presence of KCNJ5 somatic mutation and plasma TIMP-1 in APA patients. We enrolled 60 APA patients undergoing adrenalectomy, including 30 with KCNJ5 mutations (KCNJ5(+)) and 30 without (KCNJ5(-)). Clinical characteristics, echocardiographic data (including LVMI, inappropriately excessive LVMI (ieLVMI), and diastolic function) and plasma TIMP-1 levels were measured before surgery and 1 year postoperatively. The results showed that the KCNJ5(+) group had higher plasma TIMP-1 levels (P = 0.004) compared to the KCNJ5(-) group. The correlation between the KCNJ5 mutations and TIMP-1 levels remained significant after multiple regression analysis. To detect KCNJ5 mutations, receiver operating characteristic curve analysis showed TIMP-1 had the best area under the curve (AUC) value among various clinical parameters (AUC = 0.682, 95% confidence interval = 0.549-0.796, P = 0.008). Post-adrenalectomy, only the KCNJ5(+) group showed significant decrease in LVMI (P = 0.001) and log-transformed TIMP-1 levels (P = 0.035). Changes in ieLVMI before and after surgery were consistently correlated with changes in TIMP-1 levels in multivariable regression analysis. In conclusion, KCNJ5 somatic mutations in APA are associated with higher plasma TIMP-1 levels. In addition, TIMP-1 is an effective biomarker for detecting the presence of KCNJ5 mutations in APA patients.
Keywords: Aldosterone-producing adenoma; KCNJ5 somatic mutation; Myocardial fibrosis; Primary aldosteronism; Tissue inhibitor of metalloproteinases-1.
© 2024. The Author(s), under exclusive licence to The Japanese Society of Hypertension.
Conflict of interest statement
Compliance with ethical standards. Conflict of interest: The authors declare no competing interests.
References
-
- Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020. https://doi.org/10.1097/hjh.0000000000002510 .
-
- Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173:10–20. https://doi.org/10.7326/m20-0065 . - DOI - PubMed - PMC
-
- Chen ZW, Huang KC, Lee JK, Lin LC, Chen CW, Chang YY, et al. Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. J Hypertens. 2018;36:353–60. https://doi.org/10.1097/hjh.0000000000001534 . - DOI - PubMed
-
- Tsai C-H, Pan C-T, Chang Y-Y, Chen Z-W, Wu V-C, Hung C-S, et al. Left ventricular remodeling and dysfunction in primary aldosteronism. J Hum Hypertens. 2021;35:131–47. https://doi.org/10.1038/s41371-020-00426-y . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous